Medicenna Therapeutics Corp MDNA:Toronto Stock Exchange

*Data is delayed | Exchange | CAD
Last | 05/14/24 EDT
2.56UNCH (UNCH)
52 week range
0.22 - 2.89
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.56
  • 52 Week High2.89
  • 52 Week High Date05/08/24
  • 52 Week Low0.22
  • 52 Week Low Date11/01/23

Key Stats

  • Market Cap135.31M
  • Shares Out74.78M
  • 10 Day Average Volume109,994.5
  • Dividend-
  • Dividend Yield-
  • Beta2.82
  • YTD % Change509.52

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.56
  • 52 Week High2.89
  • 52 Week High Date05/08/24
  • 52 Week Low0.22
  • 52 Week Low Date11/01/23
  • Market Cap135.31M
  • Shares Out74.78M
  • 10 Day Average Volume109,994.5
  • Dividend-
  • Dividend Yield-
  • Beta2.82
  • YTD % Change509.52

RATIOS/PROFITABILITY

  • EPS (TTM)-0.22
  • P/E (TTM)-11.56
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Medicenna Therapeutics Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity...
Fahar Merchant Ph.D.
Chairman of the Board, President, Chief Executive Officer
Jeff Caravella
Chief Financial Officer
Address
2 Bloor St W., 7Th Floor
Toronto, ON
M4W 3E2
Canada

Top Peers

SYMBOLLASTCHG%CHG
CRDL
Cardiol Therapeutics Inc
2.18UNCHUNCH
DMAC
DiaMedica Therapeutics Inc
3.02-0.17-5.33%
EPRX
Eupraxia Pharmaceuticals Inc
2.95+0.05+1.72%
ONC
SVA
Sinovac Biotech Ltd
6.47-0.02-0.31%